On 24 August 2018, orphan designation (EU/3/18/2065) was granted by the European Commission to SFL Regulatory Services GmbH, Austria, for obiltoxaximab for the treatment of anthrax.
The sponsorship was transferred to SFL Pharmaceuticals Deutschland GmbH, Germany, in July 2020.
Obiltoxaximab has been authorised in the EU as Obiltoxaximab SFL since 18 November 2020.
|Disease / condition||
Treatment of anthrax
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.